Search

Your search keyword '"Bodelier, Alexander"' showing total 209 results
Start Over Author "Bodelier, Alexander"
209 results on '"Bodelier, Alexander"'

1. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial

Author

van Linschoten, Reinier C. A., Jansen, Fenna M., Pauwels, Renske W. M., Smits, Lisa J. T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G. L., Gisbertz, Ingrid A. M., Wolfhagen, Frank H. J., Römkens, Tessa E. H., Lutgens, Maurice W. M. D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G. V. M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C. J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C. I. T. L., van der Woude, C. Janneke, and Hoentjen, Frank

Published
2024
Full Text
View/download PDF

2. Interobserver agreement of current and new proposed endoscopic scores for postoperative recurrence in Crohn’s disease

Author

Bak, Michiel T.J., Hammoudi, Nassim, Allez, Matthieu, Silverberg, Mark S., Schellekens, Isa M., Erler, Nicole S., Dijkstra, Gerard, Romberg-Camps, Mariëlle, de Boer, Nanne K.H., Jansen, Sita V., van der Marel, Sander, Horjus, Carmen S., Visschedijk, Marijn C., Goetgebuer, Rogier L., van Dop, Willemijn A., Hoekstra, Jildou, Bodelier, Alexander G.L., Molendijk, Ilse, Derikx, Lauranne A.A.P., van Schaik, Fiona D.M., West, Rachel L., Duijvestein, Marjolijn, Janneke van der Woude, C., van Ruler, Oddeke, and de Vries, Annemarie C.

Published
2024
Full Text
View/download PDF

3. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial

Author

van Noord, Desirée, Hoekstra, Jildou, Kamphuis, Johannes T., Gorter, Moniek H.P., van Esch, Aura A.J., van Linschoten, Reinier C A, Jansen, Fenna M, Pauwels, Renske W M, Smits, Lisa J T, Atsma, Femke, Kievit, Wietske, de Jong, Dirk J, de Vries, Annemarie C, Boekema, Paul J, West, Rachel L, Bodelier, Alexander G L, Gisbertz, Ingrid A M, Wolfhagen, Frank H J, Römkens, Tessa E H, Lutgens, Maurice W M D, van Bodegraven, Adriaan A, Oldenburg, Bas, Pierik, Marieke J, Russel, Maurice G V M, de Boer, Nanne K, Mallant-Hent, Rosalie C, ter Borg, Pieter C J, van der Meulen-de Jong, Andrea E, Jansen, Jeroen M, Jansen, Sita V, Tan, Adrianus C I T L, van der Woude, C Janneke, and Hoentjen, Frank

Published
2023
Full Text
View/download PDF

4. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

Author

Schlotter, Malena, van Workum, Martine, de Jong, Dirk, van Dop, Willemijn, van der Marel, S., El Ghabzouri, Hayat, Talhaoui, Kamila, Oldenburg, Bas, Boontje, Nynke, Fidder, Herma, Hirdes, Meike, Creemers, Rob H., Hoekstra, J., Smid, Jael, Mujagic, Zlatan, François-Verweij, Marthe, Schakel- van den Berge, Toos, Maljaars, Jeroen, Theeuwen, Rosaline, van den Berg, Denise, Gerretsen, Suzanne, Yocarini, Xenia, D’Haens, Geert, Lowenberg, Mark, Grootjans, Joep, Gecse, Krisztina, Bouma, Gerd, Waaijenberg, Petra, Muskens, Bart, Straatmijer, Tessa, Biemans, Vince B.C., Visschedijk, Marijn, Hoentjen, Frank, de Vries, Annemarie, van Bodegraven, Adriaan A., Bodelier, Alexander, de Boer, Nanne K.H., Dijkstra, Gerard, Festen, Noortje, Horjus, Carmen, Jansen, Jeroen M., Jharap, Bindia, Mares, Wout, van Schaik, Fiona D.M., Ponsioen, Cyriel, Romkens, Tessa, Srivastava, Nidhi, van der Voorn, Michael M.P. J.A., West, Rachel, van der Woude, Janneke, Wolvers, Marije D.J., Pierik, Marieke, van der Meulen-de Jong, Andrea E., and Duijvestein, Marjolijn

Published
2023
Full Text
View/download PDF

5. Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn’s disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy

Author

ten Bokkel Huinink, Sebastiaan., Beelen, Evelien M.J., ten Bokkel Huinink, Thomas, Hoentjen, Frank, G. L. Bodelier, Alexander, Dijkstra, Gerard, Romberg-Camps, Marielle, de Boer, Nanne K., Stassen, Laurents P.S., van der Meulen, Andrea E., West, Rachel, van Ruler, Oddeke, van der Woude, C. Janneke, and de Vries, Annemarie C.

Published
2023
Full Text
View/download PDF

6. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn’s disease

Author

ten Bokkel Huinink, Sebastiaan, de Jong, Djuna C., Nieboer, Daan, Thomassen, Doranne, Steyerberg, Ewout W., Dijkgraaf, Marcel G.W., Bodelier, Alexander G.L., West, Rachel L., Römkens, Tessa E.H., Hoentjen, Frank, Mallant, Rosalie C., van Tuyl, Bas A.C., Mares, Wout G.N., Wolfhagen, Frank H.J., Dijkstra, Gerard, Reijnders, Jurriën G.P., de Boer, Nanne K., Tan, Adriaan C.I.T.L., van Boeckel, Petra G.A., Tack, Greetje J., van Asseldonk, Dirk P., D’Haens, Geert R.A.M., van der Woude, C Janneke, Duijvestein, Marjolijn, and de Vries, Annemarie C

Published
2022
Full Text
View/download PDF

7. Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study

Author

van Linschoten, Reinier C A, primary, van der Woude, C Janneke, additional, Visser, Elyke, additional, van Leeuwen, Nikki, additional, Bodelier, Alexander G L, additional, Fitzpatrick, Claire, additional, de Jonge, Vincent, additional, Vermeulen, Hestia, additional, Verweij, K Evelyne, additional, van der Wiel, Sanne, additional, Nieboer, Daan, additional, Birnie, Erwin, additional, van der Horst, Daniëlle, additional, Hazelzet, Jan A, additional, van Noord, Desirée, additional, and West, Rachel L, additional

Published
2024
Full Text
View/download PDF

8. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease:Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial

Author

van Linschoten, Reinier C.A., Jansen, Fenna M., Pauwels, Renske W.M., Smits, Lisa J.T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G.L., Gisbertz, Ingrid A.M., Wolfhagen, Frank H.J., Römkens, Tessa E.H., Lutgens, Maurice W.M.D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G.V.M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C.J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C.I.T.L., van der Woude, C. Janneke, Hoentjen, Frank, van Linschoten, Reinier C.A., Jansen, Fenna M., Pauwels, Renske W.M., Smits, Lisa J.T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G.L., Gisbertz, Ingrid A.M., Wolfhagen, Frank H.J., Römkens, Tessa E.H., Lutgens, Maurice W.M.D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G.V.M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C.J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C.I.T.L., van der Woude, C. Janneke, and Hoentjen, Frank

Abstract

Background: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was non-inferior to conventional dosing for persistent flares in patients with Crohn’s disease (CD) in clinical and biochemical remission. Aims: To develop a prediction model to identify patients who can successfully increase their ADA dose interval based on secondary analysis of trial data. Methods: Patients in the intervention group of the LADI trial increased ADA intervals to 3 and then to 4 weeks. The dose interval increase was defined as successful when patients had no persistent flare (> 8 weeks), no intervention-related severe adverse events, no rescue medication use during the study, and were on an increased dose interval while in clinical and biochemical remission at week 48. Prediction models were based on logistic regression with relaxed LASSO. Models were internally validated using bootstrap optimism correction. Results: We included 109 patients, of which 60.6% successfully increased their dose interval. Patients that were active smokers (odds ratio [OR] 0.90), had previous CD-related intra-abdominal surgeries (OR 0.85), proximal small bowel disease (OR 0.92), an increased Harvey-Bradshaw Index (OR 0.99) or increased faecal calprotectin (OR 0.997) were less likely to successfully increase their dose interval. The model had fair discriminative ability (AUC = 0.63) and net benefit analysis showed that the model could be used to select patients who could increase their dose interval. Conclusion: The final prediction model seems promising to select patients who could successfully increase their ADA dose interval. The model should be validated externally before it may be applied in clinical practice. Clinical Trial Registration Number: ClinicalTrials.gov, number NCT03172377.

Published
2024

9. Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn’s Disease

Author

Bak, Michiel T.J., Bokkel Huinink, Sebastiaan ten, Erler, Nicole S., Bodelier, Alexander G.L., Dijkstra, Gerard, Romberg-Camps, Mariëlle, de Boer, Nanne K.H., Hoentjen, Frank, Stassen, Laurents P.S., van der Meulen–de Jong, Andrea E., West, Rachel L., van Ruler, Oddeke, van der Woude, C. Janneke, de Vries, Annemarie C., Bak, Michiel T.J., Bokkel Huinink, Sebastiaan ten, Erler, Nicole S., Bodelier, Alexander G.L., Dijkstra, Gerard, Romberg-Camps, Mariëlle, de Boer, Nanne K.H., Hoentjen, Frank, Stassen, Laurents P.S., van der Meulen–de Jong, Andrea E., West, Rachel L., van Ruler, Oddeke, van der Woude, C. Janneke, and de Vries, Annemarie C.

Abstract

IntroductionThe prognostic value of the modified Rutgeerts score (mRS) in patients with Crohn's disease (CD) needs to be further elucidated. This study assessed the prognostic value of the mRS for long-term outcomes after primary ileocecal resection in patients with CD.METHODS: Patients with CD after primary ileocecal resection with an available mRS at first postoperative ileocolonoscopy (index mRS) were retrospectively included. The primary outcome was surgical recurrence. Secondary outcomes were clinical recurrence and progression to severe endoscopic recurrence (‡i3). Cox proportional hazard models were used to assess the association between index mRS and outcomes. RESULTS: Six hundred fifty-two patients were included (mean follow-up: 6.4 years, SD: 4.6). Surgical recurrence rates were 7.7%, 5.3%, 12.9%, 19.1%, 28.8%, 47.8% for index mRS i0, i1, i2a, i2b, i3, and i4, respectively. Clinical recurrence occurred in 42.2% (i0), 53.7% (i1), 58.5% (i2a), 80.2% (i2b), 79.4% (i3), and 95.3% (i4) of patients. Progression to severe endoscopic recurrence occurred in 21.1% (i0), 33.9% (i1), 26.8% (i2a), and 33.3% (i2b) of patients. An index mRS of i2b (adjusted hazard ratio [aHR] 3.0; 1.5–5.6), i3 (aHR 4.0; 2.0–7.9) and i4 (aHR 8.0; 4.0–16.0) were associated with surgical recurrence. An index mRS of i1 (aHR 1.7; 1.2–2.4), i2a (aHR 1.7; 1.2–2.4), i2b (aHR 4.4; 3.2–6.0), i3 (aHR 3.6; 2.5–5.2), and i4 (aHR 7.3; 4.8–10.9) were associated with clinical recurrence. An index mRS of i1 (aHR 2.0; 1.1–3.7) or i2b (aHR 2.5; 1.4–4.6) was associated with progression to severe endoscopic recurrence.DISCUSSION: The increasing mRS corresponds closely with the risk of surgical and clinical recurrence.

Published
2024

13. Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease

Author

Beelen, Evelien M J, primary, Arkenbosch, Jeanine H C, additional, Erler, Nicole S, additional, Sleutjes, Jasmijn A M, additional, Hoentjen, Frank, additional, Bodelier, Alexander G L, additional, Dijkstra, Gerard, additional, Romberg-Camps, Marielle, additional, de Boer, Nanne K, additional, Stassen, Laurents P S, additional, van der Meulen, Andrea E, additional, West, Rachel, additional, van Ruler, Oddeke, additional, van der Woude, C Janneke, additional, and de Vries, Annemarie C, additional

Published
2023
Full Text
View/download PDF

14. Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease.

Author

Bak, Michiel T. J., ten Bokkel Huinink, Sebastiaan, Erler, Nicole S., Bodelier, Alexander G. L., Dijkstra, Gerard, Romberg-Camps, Mariëelle, de Boer, Nanne K. H., Hoentjen, Frank, Stassen, Laurents P. S., van der Meulen-de Jong, Andrea E., West, Rachel L., van Ruler, Oddeke, van der Woude, C. Janneke, and de Vries, Annemarie C.

Published
2024
Full Text
View/download PDF

15. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial

Author

Jansen, Fenna M, primary, van Linschoten, Reinier C A, additional, Kievit, Wietske, additional, Smits, Lisa J T, additional, Pauwels, Renske W M, additional, de Jong, Dirk J, additional, de Vries, Annemarie C, additional, Boekema, Paul J, additional, West, Rachel L, additional, Bodelier, Alexander G L, additional, Gisbertz, Ingrid A M, additional, Wolfhagen, Frank H J, additional, Römkens, Tessa E H, additional, Lutgens, Maurice W M D, additional, van Bodegraven, Adriaan A, additional, Oldenburg, Bas, additional, Pierik, Marieke J, additional, Russel, Maurice G V M, additional, de Boer, Nanne K, additional, Mallant-Hent, Rosalie C, additional, ter Borg, Pieter C J, additional, van der Meulen-de Jong, Andrea E, additional, Jansen, Jeroen M, additional, Jansen, Sita V, additional, Tan, Adrianus C I T L, additional, Hoentjen, Frank, additional, and van der Woude, C Janneke, additional

Published
2023
Full Text
View/download PDF

17. Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy

Author

Huinink, Sebastiaan ten Bokkel, Beelen, Evelien M.J., Huinink, Thomas ten Bokkel, Hoentjen, F., Bodelier, Alexander G.L., Dijkstra, Gerard, Janneke van der Woude, C., Vries, Annemarie C. de, Huinink, Sebastiaan ten Bokkel, Beelen, Evelien M.J., Huinink, Thomas ten Bokkel, Hoentjen, F., Bodelier, Alexander G.L., Dijkstra, Gerard, Janneke van der Woude, C., and Vries, Annemarie C. de

Abstract

Item does not contain fulltext

Published
2023

18. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission:The Randomized Controlled LADI Trial

Author

Jansen, Fenna M., Van Linschoten, Reinier C.A., Kievit, Wietske, Smits, Lisa J.T., Pauwels, Renske W.M., De Jong, Dirk J., De Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G.L., Gisbertz, Ingrid A.M., Wolfhagen, Frank H.J., Römkens, Tessa E.H., Lutgens, Maurice W.M.D., Van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G.V.M., De Boer, Nanne K., Mallant-Hent, Rosalie C., Ter Borg, Pieter C.J., Van Der Meulen-De Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C.I.T.L., Hoentjen, Frank, Van Der Woude, C. Janneke, Van Noord, Desirée, Hoekstra, Jildou, Kamphuis, Johannes T., Gorter, Moniek H.P., Van Esch, Aura A.J., Jansen, Fenna M., Van Linschoten, Reinier C.A., Kievit, Wietske, Smits, Lisa J.T., Pauwels, Renske W.M., De Jong, Dirk J., De Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G.L., Gisbertz, Ingrid A.M., Wolfhagen, Frank H.J., Römkens, Tessa E.H., Lutgens, Maurice W.M.D., Van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G.V.M., De Boer, Nanne K., Mallant-Hent, Rosalie C., Ter Borg, Pieter C.J., Van Der Meulen-De Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C.I.T.L., Hoentjen, Frank, Van Der Woude, C. Janneke, Van Noord, Desirée, Hoekstra, Jildou, Kamphuis, Johannes T., Gorter, Moniek H.P., and Van Esch, Aura A.J.

Abstract

Background and Aims: We aimed to assess cost-effectiveness of increasing adalimumab dose intervals compared to the conventional dosing interval in patients with Crohn's disease [CD] in stable clinical and biochemical remission. Design: We conducted a pragmatic, open-label, randomized controlled non-inferiority trial, comparing increased adalimumab intervals with the 2-weekly interval in adult CD patients in clinical remission. Quality of life was measured with the EQ-5D-5L. Costs were measured from a societal perspective. Results are shown as differences and incremental net monetary benefit [iNMB] at relevant willingness to accept [WTA] levels. Results: We randomized 174 patients to the intervention [n=113] and control [n=61] groups. No difference was found in utility (difference: -0.017, 95% confidence interval [-0.044; 0.004]) and total costs (-€943, [-€2226; €1367]) over the 48-week study period between the two groups. Medication costs per patient were lower (-€2545, [-€2780; -€2192]) in the intervention group, but non-medication healthcare (+€474, [+€149; +€952]) and patient costs (+€365 [+€92; €1058]) were higher. Cost-utility analysis showed that the iNMB was €594 [-€2099; €2050], €69 [-€2908; €1965] and -€455 [-€4,096; €1984] at WTA levels of €20 000, €50 000 and €80 000, respectively. Increasing adalimumab dose intervals was more likely to be cost-effective at WTA levels below €53 960 per quality-adjusted life year. Above €53 960 continuing the conventional dose interval was more likely to be cost-effective. Conclusion: When the loss of a quality-adjusted life year is valued at less than €53 960, increasing the adalimumab dose interval is a cost-effective strategy in CD patients in stable clinical and biochemical remission. Clinical Trial Registration Number: ClinicalTrials.gov, number NCT03172377.

Published
2023

19. Impact of timing of primary ileocecal resection on prognosis in patients with Crohn's disease

Author

Beelen, Evelien M.J., Arkenbosch, Jeanine H.C., Erler, Nicole S., Sleutjes, Jasmijn A.M., Hoentjen, Frank, Bodelier, Alexander G.L., Dijkstra, Gerard, Romberg-Camps, Marielle, de Boer, Nanne K., Stassen, Laurents P.S., van der Meulen, Andrea E., West, Rachel, van Ruler, Oddeke, van der Woude, C. Janneke, de Vries, Annemarie C., Beelen, Evelien M.J., Arkenbosch, Jeanine H.C., Erler, Nicole S., Sleutjes, Jasmijn A.M., Hoentjen, Frank, Bodelier, Alexander G.L., Dijkstra, Gerard, Romberg-Camps, Marielle, de Boer, Nanne K., Stassen, Laurents P.S., van der Meulen, Andrea E., West, Rachel, van Ruler, Oddeke, van der Woude, C. Janneke, and de Vries, Annemarie C.

Abstract

BACKGROUND: The advantage of early ileocecal resection after Crohn's disease diagnosis is a matter of debate. This study aims to assess the timing of ileocecal resection on prognosis, after correction for possible confounders. METHODS: Patients with Crohn's disease with primary ileocecal resection between 2000 and 2019 were included in a retrospective multicentre cohort. The primary endpoint was endoscopic recurrence (Rutgeerts score ≥i2b) within 18 months. Secondary endpoints were escalation of inflammatory bowel disease medication within 18 months and re-resection during follow-up. The association between timing of ileocecal resection and these endpoints was investigated using multivariable proportional hazard models, corrected for covariates including Montreal classification, postoperative prophylaxis, smoking, indication for surgery, medication before ileocecal resection, perianal fistulas, surgical approach, histology, length of resected segment and calendar year. RESULTS:In 822 patients ileocecal resection was performed after a median of 3.1 years (i.q.r. 0.7-8.0) after Crohn's disease diagnosis. The lowest incidence of endoscopic recurrence, escalation of inflammatory bowel disease medication and re-resection was observed for patients undergoing ileocecal resection shortly after diagnosis (0-1 months). After correction for covariates, patients with ileocecal resection at 0, 4 and 12 months after diagnosis had a cumulative incidence of 35 per cent, 48 per cent and 39 per cent for endoscopic recurrence, 20 per cent, 29 per cent and 28 per cent for escalation of inflammatory bowel disease medication and 20 per cent, 30 per cent and 34 per cent for re-resection, respectively. In the multivariable model ileocolonic disease (HR 1.39 (95 per cent c.i. 1.05 to 1.86)), microscopic inflammation of proximal and distal resection margins (HR 2.20 (95 per cent c.i. 1.21 to 3.87)) and postoperative prophylactic biol

Published
2023

20. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry

Author

Cancer, CMM Sectie Molecular Cancer Research, MS MDL 1, Infection & Immunity, Unit Opleiding Aios, Straatmijer, Tessa, van Schaik, Fiona D.M., Bodelier, Alexander G.L., Visschedijk, Marijn, de Vries, Annemarie C., Ponsioen, Cyriel Y., Pierik, Marieke, van Bodegraven, Ad A., West, Rachel L., de Boer, Nanne K.H., Srivastava, Nidhi, Romkens, Tessa E.H., Hoekstra, Jildou, Oldenburg, Bas, Dijkstra, Gerard, van der Woude, Janneke C., Löwenberg, Mark, Mujagic, Zlatan, Biemans, Vince B.C., van der Meulen-de Jong, Andrea E., Duijvestein, Marjolijn, Cancer, CMM Sectie Molecular Cancer Research, MS MDL 1, Infection & Immunity, Unit Opleiding Aios, Straatmijer, Tessa, van Schaik, Fiona D.M., Bodelier, Alexander G.L., Visschedijk, Marijn, de Vries, Annemarie C., Ponsioen, Cyriel Y., Pierik, Marieke, van Bodegraven, Ad A., West, Rachel L., de Boer, Nanne K.H., Srivastava, Nidhi, Romkens, Tessa E.H., Hoekstra, Jildou, Oldenburg, Bas, Dijkstra, Gerard, van der Woude, Janneke C., Löwenberg, Mark, Mujagic, Zlatan, Biemans, Vince B.C., van der Meulen-de Jong, Andrea E., and Duijvestein, Marjolijn

Published
2023

21. Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy

Author

Ten Bokkel Huinink, Sebastiaan, Beelen, Evelien M J, Ten Bokkel Huinink, Thomas, Hoentjen, Frank, G L Bodelier, Alexander, Dijkstra, Gerard, Romberg-Camps, Marielle, de Boer, Nanne K, Stassen, Laurents P S, van der Meulen, Andrea E, West, Rachel, van Ruler, Oddeke, van der Woude, C Janneke, de Vries, Annemarie C, Dutch Initiative on Crohn and Colitis (ICC), Ten Bokkel Huinink, Sebastiaan, Beelen, Evelien M J, Ten Bokkel Huinink, Thomas, Hoentjen, Frank, G L Bodelier, Alexander, Dijkstra, Gerard, Romberg-Camps, Marielle, de Boer, Nanne K, Stassen, Laurents P S, van der Meulen, Andrea E, West, Rachel, van Ruler, Oddeke, van der Woude, C Janneke, de Vries, Annemarie C, and Dutch Initiative on Crohn and Colitis (ICC)

Abstract

BACKGROUND: A considerable proportion of Crohn's disease patients that undergo ileocecal resection (ICR) have failed anti-tumor necrosis factor (TNF) therapy preoperatively. This study aimed to assess the effectiveness of retreatment of anti-TNF therapy in patients with postoperative recurrence.METHODS: A real-world cohort study was performed on Crohn's disease patients who underwent primary ICR after anti-TNF therapy failure, and who were retreated with anti-TNF therapy for postoperative symptomatic Crohn's disease. The primary outcome was treatment failure (the need for (re)introduction of corticosteroids, immunosuppressants, or biologicals or the need for re-resection). Sub-analyses were performed on the nature of preoperative anti-TNF failure (primary non-response, secondary loss of response, intolerance), indication for ICR (refractory, stricturing, penetrating disease), combination therapy with immunomodulators, retreatment with the same anti-TNF agent and preoperative exposure to 1 vs. >1 anti-TNF agents.RESULTS: In total, 66 of 364 patients retreated with anti-TNF therapy following ICR. Cumulative rates of treatment failure at 1 and 2 years were 28% and 47%. Treatment failure rate at 2 years was significantly lower in patients receiving combination therapy as compared to anti-TNF monotherapy (30% vs. 49%, P = 0.02). No difference in treatment failure was found with regards to the nature of preoperative anti-TNF failure (P = 0.76), indication for ICR (P = 0.88) switch of anti-TNF agent (P = 0.55) agent, and preoperative exposure to 1 vs. >1 anti-TNF agents (P = 0.88).CONCLUSION: Retreatment with anti-TNF therapy for postoperative Crohn's disease recurrence is a valid strategy after preoperative failure. Combination therapy is associated with a lower rate of treatment failure.

Published
2023

22. Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial

Author

Walter, Daisy, van Boeckel, Petra G.A., Groenen, Marcel J., Weusten, Bas L.A.M., Witteman, Ben J., Tan, Gi, Brink, Menno A., Nicolai, Jan, Tan, Adriaan C., Alderliesten, Joyce, Venneman, Niels G., Laleman, Wim, Jansen, Jeroen M., Bodelier, Alexander, Wolters, Frank L., van der Waaij, Laurens A., Breumelhof, Ronald, Peters, Frank T.M., Scheffer, Robbert C.H., Leenders, Max, Hirdes, Meike M.C., Steyerberg, Ewout W., Vleggaar, Frank P., and Siersema, Peter D.

Published
2015
Full Text
View/download PDF

24. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

Author

Straatmijer, Tessa, primary, Biemans, Vince B.C., additional, Visschedijk, Marijn, additional, Hoentjen, Frank, additional, de Vries, Annemarie, additional, van Bodegraven, Adriaan A., additional, Bodelier, Alexander, additional, de Boer, Nanne K.H., additional, Dijkstra, Gerard, additional, Festen, Noortje, additional, Horjus, Carmen, additional, Jansen, Jeroen M., additional, Jharap, Bindia, additional, Mares, Wout, additional, van Schaik, Fiona D.M., additional, Ponsioen, Cyriel, additional, Romkens, Tessa, additional, Srivastava, Nidhi, additional, van der Voorn, Michael M.P. J.A., additional, West, Rachel, additional, van der Woude, Janneke, additional, Wolvers, Marije D.J., additional, Pierik, Marieke, additional, van der Meulen-de Jong, Andrea E., additional, Duijvestein, Marjolijn, additional, Schlotter, Malena, additional, van Workum, Martine, additional, de Jong, Dirk, additional, van Dop, Willemijn, additional, van der Marel, S., additional, El Ghabzouri, Hayat, additional, Talhaoui, Kamila, additional, Oldenburg, Bas, additional, Boontje, Nynke, additional, Fidder, Herma, additional, Hirdes, Meike, additional, Creemers, Rob H., additional, Hoekstra, J., additional, Smid, Jael, additional, Mujagic, Zlatan, additional, François-Verweij, Marthe, additional, Schakel- van den Berge, Toos, additional, Maljaars, Jeroen, additional, Theeuwen, Rosaline, additional, van den Berg, Denise, additional, Gerretsen, Suzanne, additional, Yocarini, Xenia, additional, D’Haens, Geert, additional, Lowenberg, Mark, additional, Grootjans, Joep, additional, Gecse, Krisztina, additional, Bouma, Gerd, additional, Waaijenberg, Petra, additional, and Muskens, Bart, additional

Published
2023
Full Text
View/download PDF

25. Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry

Author

Straatmijer, Tessa, primary, van Schaik, Fiona D. M., additional, Bodelier, Alexander G. L., additional, Visschedijk, Marijn, additional, de Vries, Annemarie C., additional, Ponsioen, Cyriel Y., additional, Pierik, Marieke, additional, van Bodegraven, Ad A., additional, West, Rachel L., additional, de Boer, Nanne K. H., additional, Srivastava, Nidhi, additional, Romkens, Tessa E. H., additional, Hoekstra, Jildou, additional, Oldenburg, Bas, additional, Dijkstra, Gerard, additional, van der Woude, Janneke C., additional, Löwenberg, Mark, additional, Mujagic, Zlatan, additional, Biemans, Vince B. C., additional, van der Meulen‐de Jong, Andrea E., additional, and Duijvestein, Marjolijn, additional

Published
2022
Full Text
View/download PDF

26. Higher quality of life after metal stent placement compared with plastic stent placement for malignant extrahepatic bile duct obstruction: a randomized controlled trial

Author

Walter, Daisy, van Boeckel, Petra G.A., Groenen, Marcel J.M., Weusten, Bas L.A.M., Witteman, Ben J., Tan, Gi, Brink, Menno A., Nicolai, Jan, Tan, Adriaan C., Alderliesten, Joyce, Venneman, Niels G., Laleman, Wim, Jansen, Jeroen M., Bodelier, Alexander, Wolters, Frank L., van der Waaij, Laurens A., Breumelhof, Ronald, Peters, Frans T.M., Scheffer, Robbert C.H., Steyerberg, Ewout W., May, Anne M., Leenders, Max, Hirdes, Meike M.C., Vleggaar, Frank P., and Siersema, Peter D.

Published
2017
Full Text
View/download PDF

27. Tu1818 POSTOPERATIVE PROPHYLAXIS PREVENTS SURGICAL AND SEVERE ENDOSCOPIC RECURRENCE AFTER PRIMARY ILEOCECAL RESECTION IN CROHN'S DISEASE

Author

Huinink, Sebastiaan ten Bokkel, Bak, Michiel T., Beelen, Evelien, Erler, Nicole S., Hoentjen, Frank, Bodelier, Alexander, Dijkstra, Gerard, Romberg-Camps, Mariëlle, de Boer, Nanne, Stassen, Laurents P., De Jong, Andrea V. Meulen, West, Rachel, van Ruler, Oddeke, Van Der Woude, Christien Janneke, and De Vries, Annemarie C.

Published
2024
Full Text
View/download PDF

28. Mo1770 INTEROBSERVER AGREEMENT OF CURRENT AND NEW PROPOSED ENDOSCOPIC SCORES FOR POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE

Author

Bak, Michiel T., Hammoudi, Nassim, Allez, Matthieu, Silverberg, Mark S., Erler, Nicole S., Dijkstra, Gerard, Romberg-Camps, Mariëlle, de Boer, Nanne, Jansen, Sita, van der marel, Sander, Horje, Carmen S. Horjus Talabur, Visschedijk, Marijn C., Goetgebuer, Rogier, van Dop, Willemijn A., Hoekstra, Jildou, Bodelier, Alexander, Molendijk, Ilse, Derikx, Lauranne, Van Schaik, Fiona, West, Rachel, Duijvestein, Marjolijn, Van Der Woude, Christien Janneke, van Ruler, Oddeke, and De Vries, Annemarie C.

Published
2024
Full Text
View/download PDF

29. Lower Risk of Recurrence with a Higher Induction Dose of Mesalazine and Longer Duration of Treatment in Ulcerative Colitis: Results from the Dutch, Non-Interventional, IMPACT Study

Author

West, Rachel, primary, Russel, Maurice, primary, Bodelier, Alexander, primary, Kuijvenhoven, Johan, primary, Bruin, Karlien, primary, Jansen, Jeroen, primary, Van der Meulen, Andrea, primary, Keulen, Eric, primary, Wolters, Leonieke, primary, Ouwendijk, Robert, primary, Bezemer, Geert, primary, Koussoulas, Vassilis, primary, Tang, Thjon, primary, Van Dobbenburgh, Aart, primary, Van Nistelrooy, Marianne, primary, Minderhoud, Itta, primary, Vandebosch, Sigrid, primary, and Lubbinge, Hans, primary

Published
2022
Full Text
View/download PDF

30. Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West

Author

Arkenbosch, Jeanine H C, primary, Mak, Joyce W Y, additional, Ho, Jacky C L, additional, Beelen, Evelien M J, additional, Erler, Nicole S, additional, Hoentjen, Frank, additional, Bodelier, Alexander G L, additional, Dijkstra, Gerard, additional, Romberg-Camps, Mariëlle, additional, de Boer, Nanne K H, additional, Stassen, Laurents P S, additional, van der Meulen, Andrea E, additional, West, Rachel, additional, van Ruler, Oddeke, additional, van der Woude, Christien Janneke, additional, Ng, Siew C, additional, and de Vries, Annemarie C, additional

Published
2021
Full Text
View/download PDF

31. Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study

Author

Biemans, Vince B.C., van der Woude, C. Janneke, Dijkstra, Gerard, van der Meulen‐de Jong, Andrea E., Oldenburg, Bas, de Boer, Nanne K., Löwenberg, Mark, Srivastava, Nidhi, Bodelier, Alexander G.L., West, Rachel L., Jansen, Jeroen M., de Vries, Annemarie C., Haans, Jeoffrey J.L., de Jong, Dirk J., Pierik, Marie J., and Hoentjen, Frank

Subjects
Adult, Male, Research, Articles, Middle Aged, Antibodies, Monoclonal, Humanized, Article, Cohort Studies, Treatment Outcome, Crohn Disease, Gastrointestinal Agents, Humans, Colitis, Ulcerative, Drug Therapy, Combination, Female, Prospective Studies, Registries, Immunosuppressive Agents, Follow-Up Studies
Abstract

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index ≤ 4, Short Clinical Colitis Activity index ≤ 2) at weeks 52 and 104 were 28% and 19% for CD and 27% and 28% for UC, respectively. Fifty-nine percent maintained corticosteroid-free clinical remission between weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD and 28% for UC after 2 years of follow-up regardless of concomitant immunosuppression.

Published
2019

32. Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry.

Author

Straatmijer, Tessa, van Schaik, Fiona D. M., Bodelier, Alexander G. L., Visschedijk, Marijn, de Vries, Annemarie C., Ponsioen, Cyriel Y., Pierik, Marieke, van Bodegraven, Ad A., West, Rachel L., de Boer, Nanne K. H., Srivastava, Nidhi, Romkens, Tessa E. H., Hoekstra, Jildou, Oldenburg, Bas, Dijkstra, Gerard, van der Woude, Janneke C., Löwenberg, Mark, Mujagic, Zlatan, Biemans, Vince B. C., and van der Meulen‐de Jong, Andrea E.

Subjects
ULCERATIVE colitis, HERPES zoster, DISEASE remission, C-reactive protein, CALPROTECTIN
Abstract

Summary: Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment. Aim: The aim of this study was to assess the effectiveness and safety of 24 months of tofacitinib use in UC patients in the Netherlands. Methods: Patients initiating tofacitinib treatment were included in the ICC Registry, a nationwide, observational registry. Patients were prospectively evaluated for up to 24 months. The primary outcome was corticosteroid‐free clinical remission (CSFR, Simple Clinical Colitis Activity Index [SCCAI] ≤2) at week 104. Secondary outcomes included biochemical remission (C‐reactive protein (CRP) ≤5 mg/L and faecal calprotectin (FC) ≤250 μg/g), safety, and discontinuation rate. Results: We included 110 patients of whom 104 (94.5%) were anti‐TNF experienced. After 104 weeks of tofacitinib, 31.8% (34/107) were in CSFR, 23.4% (25/107) in biochemical remission and 18.7% (20/107) in combined clinical and biochemical remission. Of the patients in CSFR at week 52, 76.5% (26/34) remained so after 104 weeks of treatment. Sixty‐one patients (55.5%) discontinued tofacitinib after a median duration of 13 weeks (IQR 7–34). The main reasons for discontinuation were non‐response (59%), loss of response (14.8%), and adverse events (18%). There were 33.9 possible tofacitinib‐related adverse events per 100 patient‐years during follow‐up. Adverse events most probably related to tofacitinib were skin reactions and headaches. There were 6.4 herpes zoster infections per 100 patient‐years. Conclusion: Tofacitinib was effective in 31.8% of patients after 24 months of treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study

Author

Straatmijer, Tessa, Biemans, V.B.C., Hoentjen, F., Boer, Nanne K.H. de, Bodelier, Alexander G.L., Dijkstra, Gerard, Dop, W.A. van, Duijvestein, Marjolijn, Meulen-de Jong, Andrea E. van der, Straatmijer, Tessa, Biemans, V.B.C., Hoentjen, F., Boer, Nanne K.H. de, Bodelier, Alexander G.L., Dijkstra, Gerard, Dop, W.A. van, Duijvestein, Marjolijn, and Meulen-de Jong, Andrea E. van der

Abstract

Item does not contain fulltext

Published
2021

34. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study

Author

MS MDL 1, Infection & Immunity, Straatmijer, Tessa, Biemans, Vince B.C., Hoentjen, Frank, De Boer, Nanne K.H., Bodelier, Alexander G.L., Dijkstra, Gerard, Van Dop, Willemijn A., Haans, Jeoffrey J.L., Jansen, Jeroen M., Maljaars, P. W.Jeroen, Van Der Marel, Sander, Oldenburg, Bas, Ponsioen, Cyriel Y., Visschedijk, Marijn C., De Vries, Annemarie C., West, Rachel L., Van Der Woude, C. Janneke, Pierik, Marieke, Duijvestein, Marjolijn, Van Der Meulen-De Jong, Andrea E., MS MDL 1, Infection & Immunity, Straatmijer, Tessa, Biemans, Vince B.C., Hoentjen, Frank, De Boer, Nanne K.H., Bodelier, Alexander G.L., Dijkstra, Gerard, Van Dop, Willemijn A., Haans, Jeoffrey J.L., Jansen, Jeroen M., Maljaars, P. W.Jeroen, Van Der Marel, Sander, Oldenburg, Bas, Ponsioen, Cyriel Y., Visschedijk, Marijn C., De Vries, Annemarie C., West, Rachel L., Van Der Woude, C. Janneke, Pierik, Marieke, Duijvestein, Marjolijn, and Van Der Meulen-De Jong, Andrea E.

Published
2021

35. Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study

Author

Straatmijer, Tessa, primary, Biemans, Vince B C, additional, Hoentjen, Frank, additional, de Boer, Nanne K H, additional, Bodelier, Alexander G L, additional, Dijkstra, Gerard, additional, van Dop, Willemijn A, additional, Haans, Jeoffrey J L, additional, Jansen, Jeroen M, additional, Maljaars, P W Jeroen, additional, van der Marel, Sander, additional, Oldenburg, Bas, additional, Ponsioen, Cyriel Y, additional, Visschedijk, Marijn C, additional, de Vries, Annemarie C, additional, West, Rachel L, additional, van der Woude, C Janneke, additional, Pierik, Marieke, additional, Duijvestein, Marjolijn, additional, and van der Meulen-de Jong, Andrea E, additional

Published
2021
Full Text
View/download PDF

36. Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West.

Author

Arkenbosch, Jeanine H C, Mak, Joyce W Y, Ho, Jacky C L, Beelen, Evelien M J, Erler, Nicole S, Hoentjen, Frank, Bodelier, Alexander G L, Dijkstra, Gerard, Romberg-Camps, Mariëlle, Boer, Nanne K H de, Stassen, Laurents P S, Meulen, Andrea E van der, West, Rachel, Ruler, Oddeke van, Woude, Christien Janneke van der, Ng, Siew C, and Vries, Annemarie C de

Published
2022
Full Text
View/download PDF

37. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study

Author

Derikx, Lauranne A A P, primary, Lantinga, Marten A, additional, de Jong, Dirk J, additional, van Dop, Willemijn A, additional, Creemers, Rob H, additional, Römkens, Tessa E H, additional, Jansen, Jeroen M, additional, Mahmmod, Nofel, additional, West, Rachel L, additional, Tan, Adriaan C I T L, additional, Bodelier, Alexander G L, additional, Gorter, Moniek H P, additional, Boekema, Paul J, additional, Halet, Eric R C, additional, Horjus, Carmen S, additional, van Dijk, Maarten A, additional, Hirdes, Meike M C, additional, Epping Stippel, Ludger S M, additional, Jharap, Bindia, additional, Lutgens, Maurice W M D, additional, Russel, Maurice G, additional, Gilissen, Lennard P L, additional, Nauta, Sjoukje, additional, van Bodegraven, Adriaan A, additional, and Hoentjen, Frank, additional

Published
2020
Full Text
View/download PDF

38. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life

Author

Kanis, Shannon Linda, primary, Modderman, Sanne, additional, Escher, Johanna C, additional, Erler, Nicole, additional, Beukers, Ruud, additional, de Boer, Nanne, additional, Bodelier, Alexander, additional, Depla, Annekatrien C T.M, additional, Dijkstra, Gerard, additional, van Dijk, Anne-Baue Ruth Margaretha, additional, Gilissen, Lennard, additional, Hoentjen, Frank, additional, Jansen, Jeroen M, additional, Kuyvenhoven, Johan, additional, Mahmmod, Nofel, additional, Mallant-Hent, Rosalie C, additional, van der Meulen-de Jong, Andrea E, additional, Noruzi, Anahita, additional, Oldenburg, Bas, additional, Oostenbrug, Liekele E, additional, Ter Borg, Pieter C.J., additional, Pierik, Marieke, additional, Romberg- Camps, Mariëlle, additional, Thijs, Willem, additional, West, Rachel, additional, de Lima, Alison, additional, and van der Woude, C Janneke, additional

Published
2020
Full Text
View/download PDF

39. 1028 USTEKINUMAB IS ASSOCIATED WITH BETTER EFFECTIVENESS OUTCOMES WHEN COMPARED TO VEDOLIZUMAB IN CROHN'S DISEASE PATIENTS WITH PRIOR FAILURE TO ANTI-TNF: A COMPARATIVE EFFECTIVENESS STUDY FROM THE DUTCH ICC REGISTRY

Author

Biemans, Vince, primary, Van Der Woude, Christien Janneke, additional, Dijkstra, Gerard, additional, de Jong, Andrea v. Meulen -, additional, Löwenberg, Mark, additional, de Boer, Nanne, additional, Oldenburg, Bas, additional, Srivastava, Nidhi, additional, Jansen, Jeroen M., additional, Bodelier, Alexander, additional, West, Rachel, additional, de Vries, Annemarie C., additional, Haans, Jeoffrey, additional, De Jong, Dirk J., additional, Hoentjen, Frank, additional, and Pierik, Marie, additional

Published
2020
Full Text
View/download PDF

40. Tu1892 TOFACITINIB FOR ULCERATIVE COLITIS: RESULTS OF THE ICC REGISTRY, A NATIONWIDE PROSPECTIVE OBSERVATIONAL COHORT STUDY

Author

Biemans, Vince, primary, Sleutjes, Jasmijn A., additional, de Vries, Annemarie C., additional, Bodelier, Alexander, additional, Dijkstra, Gerard, additional, Oldenburg, Bas, additional, Löwenberg, Mark, additional, van Bodegraven, Adriaan A., additional, de Jong, Andrea v. Meulen -, additional, de Boer, Nanne, additional, Srivastava, Nidhi, additional, West, Rachel, additional, Romkens, Tessa, additional, Horje, Carmen S. Horjus Talabur, additional, Jansen, Jeroen M., additional, Hoekstra, Jildou, additional, Weersma, Rinse K., additional, van Schaik, Fiona, additional, Hoentjen, Frank, additional, and Pierik, Marie, additional

Published
2020
Full Text
View/download PDF

41. Su1955 EAST VERSUS WEST: INDICATIONS, POSTOPERATIVE MANAGMENT AND PROGNOSIS OF CROHN'S DISEASE AFTER ILEOCECAL RESECTION

Author

Arkenbosch, Jeanine H., primary, Mak, Joyce W., additional, Beelen, Evelien, additional, Erler, Nicole S., additional, de Graaf, Eelco J., additional, Bodelier, Alexander, additional, Hoentjen, Frank, additional, Dijkstra, Gerard, additional, de Boer, Nanne, additional, Romberg-Camps, Mariëlle, additional, Van Der Woude, Christien Janneke, additional, Ng, Siew C., additional, and de Vries, Annemarie C., additional

Published
2020
Full Text
View/download PDF

42. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry

Author

Biemans, Vince B. C., Sleutjes, Jasmijn A. M., de Vries, Annemarie C., Bodelier, Alexander G. L., Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A., van der Meulen-de Jong, Andrea E., de Boer, Nanne K. H., Srivastava, Nidhi, West, Rachel L., Römkens, Tessa E. H., Horjus Talabur Horje, Carmen S., Jansen, Jeroen M., van der Woude, C. Janneke, Hoekstra, Jildou, Weersma, Rinse K., van Schaik, Fiona D. M., Hoentjen, Frank, Pierik, Marieke J., Fidder, H. H., Ponsioen, C. Y., Duijvestein, M., Romberg-Camps, M. J. L., Maljaars, P. W. J., Bouma, G., van der Marel, S., de Jong, D. J., Haans, J. J. L., Translational Immunology Groningen (TRIGR), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Groningen Institute for Organ Transplantation (GIOT), AGEM - Digestive immunity, Gastroenterology and hepatology, AGEM - Re-generation and cancer of the digestive system, AII - Inflammatory diseases, Gastroenterology & Hepatology, Gastroenterology and Hepatology, AGEM - Endocrinology, metabolism and nutrition, Interne Geneeskunde, RS: NUTRIM - R2 - Liver and digestive health, and MUMC+: MA Maag Darm Lever (9)

Subjects
medicine.medical_specialty, Gastroenterology, Vedolizumab, Interquartile range, Internal medicine, medicine, Pharmacology (medical), Adverse effect, Janus kinase inhibitor, ulcerative colitis, Tofacitinib, tofacitinib, Hepatology, business.industry, real world, medicine.disease, Tofacitinib for Ulcerative Colitis, Faecal calprotectin, Ulcerative colitis, Discontinuation, rheumatoid-arthritis, Original Article, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], medicine.drug
Abstract

Contains fulltext : 220023.pdf (Publisher’s version ) (Open Access) BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). AIM: To evaluate effectiveness, safety and use of tofacitinib in daily practice. METHODS: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid-free clinical remission (short clinical colitis activity index [SCCAI] ≤2), biochemical remission (faecal calprotectin level ≤250 µg/g), combined corticosteroid-free clinical and biochemical remission, predictors of remission, safety outcomes, treatment dose and effect on lipids were determined at weeks 12 and 24. Endoscopic outcomes were evaluated in centres with routine endoscopic evaluation. RESULTS: In total, 123 UC patients (95% anti-TNF, 62% vedolizumab and 3% ustekinumab experienced) were followed for a median duration of 24 weeks (interquartile range 12-26). The proportion of patients in corticosteroid-free clinical, biochemical, and combined corticosteroid-free clinical and biochemical remission rate at week 24 was 29% (n: 22/77), 25% (n: 14/57), and 19% (n: 11/57) respectively. Endoscopic remission (Mayo = 0) was achieved in 21% of patients at week 12 (n: 7/33). Prior vedolizumab exposure was associated with reduced clinical remission (odds ratio 0.33, 95% confidence interval [CI] 0.11-0.94). At week 24, 33% (n: 14/42) of patients still on tofacitinib treatment used 10 mg twice daily. In total, 33 tofacitinib-related adverse events (89 per 100 patient years) occurred, 7 (6% of total cohort) resulted in discontinuation. Cholesterol, HDL and LDL levels increased during induction treatment by 18% (95% CI 9-26), 18% (95% CI 8-28) and 21% (95% CI 14-39) respectively. CONCLUSION: Tofacitinib is an effective treatment for UC after anti-TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients.

Published
2020
Full Text
View/download PDF

43. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment

Author

Infection & Immunity, MS MDL 1, Biemans, Vince B C, van der Woude, C Janneke, Dijkstra, Gerard, van der Meulen-de Jong, Andrea E, Löwenberg, Mark, de Boer, Nanne K, Oldenburg, Bas, Srivastava, Nidhi, Jansen, Jeroen M, Bodelier, Alexander G L, West, Rachel L, de Vries, Annemarie C, Haans, Jeoffrey J L, de Jong, Dirk, Hoentjen, Frank, Pierik, Marieke J, Dutch Initiative on Crohn and Colitis (ICC), Infection & Immunity, MS MDL 1, Biemans, Vince B C, van der Woude, C Janneke, Dijkstra, Gerard, van der Meulen-de Jong, Andrea E, Löwenberg, Mark, de Boer, Nanne K, Oldenburg, Bas, Srivastava, Nidhi, Jansen, Jeroen M, Bodelier, Alexander G L, West, Rachel L, de Vries, Annemarie C, Haans, Jeoffrey J L, de Jong, Dirk, Hoentjen, Frank, Pierik, Marieke J, and Dutch Initiative on Crohn and Colitis (ICC)

Published
2020

44. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry

Author

MS MDL 1, Infection & Immunity, Biemans, Vince B C, Sleutjes, Jasmijn A M, de Vries, Annemarie C, Bodelier, Alexander G L, Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A, van der Meulen-de Jong, Andrea E, de Boer, Nanne K H, Srivastava, Nidhi, West, Rachel L, Römkens, Tessa E H, Horjus Talabur Horje, Carmen S, Jansen, Jeroen M, van der Woude, C Janneke, Hoekstra, Jildou, Weersma, Rinse K, van Schaik, Fiona D M, Hoentjen, Frank, Pierik, Marieke J, Dutch Initiative on Crohn and Colitis (ICC), MS MDL 1, Infection & Immunity, Biemans, Vince B C, Sleutjes, Jasmijn A M, de Vries, Annemarie C, Bodelier, Alexander G L, Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A, van der Meulen-de Jong, Andrea E, de Boer, Nanne K H, Srivastava, Nidhi, West, Rachel L, Römkens, Tessa E H, Horjus Talabur Horje, Carmen S, Jansen, Jeroen M, van der Woude, C Janneke, Hoekstra, Jildou, Weersma, Rinse K, van Schaik, Fiona D M, Hoentjen, Frank, Pierik, Marieke J, and Dutch Initiative on Crohn and Colitis (ICC)

Published
2020

45. Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

Author

Biemans, Vince B C, primary, van der Meulen - de Jong, Andrea E, primary, van der Woude, Christine J, primary, Löwenberg, Mark, primary, Dijkstra, Gerard, primary, Oldenburg, Bas, primary, de Boer, Nanne K H, primary, van der Marel, Sander, primary, Bodelier, Alexander G L, primary, Jansen, Jeroen M, primary, Haans, Jeoffrey J L, primary, Theeuwen, Rosaline, primary, de Jong, Dirk, primary, Pierik, Marie J, primary, and Hoentjen, Frank, primary

Published
2019
Full Text
View/download PDF

47. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.

Author

Kanis, Shannon Linda, Modderman, Sanne, Escher, Johanna C., Erler, Nicole, Beukers, Ruud, de Boer, Nanne, Bodelier, Alexander, Depla, Annekatrien C. T. M., Dijkstra, Gerard, van Dijk, Anne-Baue Ruth Margaretha, Gilissen, Lennard, Hoentjen, Frank, Jansen, Jeroen M., Kuyvenhoven, Johan, Mahmmod, Nofel, Mallant-Hent, Rosalie C., van der Meulen-de, Andrea E., Noruzi, Anahita, Oldenburg, Bas, and Oostenbrug, Liekele E.

Subjects
INFLAMMATORY bowel diseases, MOTHER-child relationship, IMMUNIZATION of children, TYPE 1 diabetes, SMALL for gestational age, LOW birth weight, PEDIATRIC gastroenterology
Published
2021
Full Text
View/download PDF

48. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.

Author

Derikx, Lauranne A A P, Lantinga, Marten A, Jong, Dirk J de, Dop, Willemijn A van, Creemers, Rob H, Römkens, Tessa E H, Jansen, Jeroen M, Mahmmod, Nofel, West, Rachel L, Tan, Adriaan C I T L, Bodelier, Alexander G L, Gorter, Moniek H P, Boekema, Paul J, Halet, Eric R C, Horjus, Carmen S, Dijk, Maarten A van, Hirdes, Meike M C, Stippel, Ludger S M Epping, Jharap, Bindia, and Lutgens, Maurice W M D

Abstract

Background and Aims The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population. Methods We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population. Results We established an IBD cohort of 34 763 patients. COVID-19 was diagnosed in 100/34 763 patients [0.29%]; 20/100 of these patients [20%] had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalisation occurred in 59/100 [59.0%] patients and 13/100 [13.0%] died. All patients who died had comorbidities and all but one were ≥65 years old. In line, we identified ≥1 comorbidity as an independent risk factor for hospitalisation (odds ratio [OR] 4.20, 95% confidence interval [CI] 1.58–11.17,; p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 [95% CI 236.6–349.7] versus 333.0 [95% CI 329.3–336.7] per 100000 patients, respectively; p = 0.15). Conclusions Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% were hospitalised and 13% died. A comparable COVID-19 risk was found between the IBD cohort [100/34 763 = 0.29%] and the general Dutch population. The presence of ≥1 comorbidities was an independent risk factor for hospitalisation due to COVID-19. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study.

Author

Asscher, Vera E. R., Biemans, Vince B. C., Pierik, Marieke J., Dijkstra, Gerard, Löwenberg, Mark, Marel, Sander, Boer, Nanne K. H., Bodelier, Alexander G. L., Jansen, Jeroen M., West, Rachel L., Haans, Jeoffrey J. L., Dop, Willemijn A., Weersma, Rinse K., Hoentjen, Frank, and Maljaars, P. W. Jeroen

Subjects
COMORBIDITY, INFLAMMATORY bowel diseases, DISEASE remission, COHORT analysis
Abstract

Summary: Background: Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). Aims: To evaluate the association between age and comorbidity with safety and effectiveness outcomes of vedolizumab and ustekinumab in IBD. Methods: IBD patients initiating vedolizumab or ustekinumab in regular care were enrolled prospectively. Comorbidity prevalence was assessed using the Charlson Comorbidity Index (CCI). Association between age and CCI, both continuously assessed, with safety outcomes (any infection, hospitalisation, adverse events) during treatment, and effectiveness outcomes (clinical response and remission, corticosteroid‐free remission, clinical remission combined with biochemical remission) after 52 weeks of treatment were evaluated. Multivariable logistic regression was used to adjust for confounders. Results: We included 203 vedolizumab‐ and 207 ustekinumab‐treated IBD patients, mean age 42.2 (SD 16.0) and 41.6 (SD 14.4). Median treatment duration 54.0 (IQR 19.9‐104.0) and 48.4 (IQR 24.4‐55.1) weeks, median follow‐up time 104.0 (IQR 103.1‐104.0) and 52.0 weeks (IQR 49.3‐100.4). On vedolizumab, CCI associated independently with any infection (OR 1.387, 95% CI 1.022‐1.883, P = 0.036) and hospitalisation (OR 1.586, 95% CI 1.127‐2.231, P = 0.008). On ustekinumab, CCI associated independently with hospitalisation (OR 1.621, 95% CI 1.034‐2.541, P = 0.035). CCI was not associated with effectiveness, and age was not associated with any outcomes. Conclusions: Comorbidity ‐ but not age ‐ is associated with an increased risk of hospitalisations on either treatment, and with any infection on vedolizumab. This underlines the importance of comorbidity assessment and safety monitoring of IBD patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti‐TNF treatment.

Author

Biemans, Vince B. C., Woude, C. Janneke, Dijkstra, Gerard, Meulen‐de Jong, Andrea E., Löwenberg, Mark, Boer, Nanne K., Oldenburg, Bas, Srivastava, Nidhi, Jansen, Jeroen M., Bodelier, Alexander G. L., West, Rachel L., Vries, Annemarie C., Haans, Jeoffrey J. L., Jong, Dirk, Hoentjen, Frank, and Pierik, Marieke J.

Subjects
CROHN'S disease, DISEASE remission, INFLAMMATORY bowel diseases, PROPENSITY score matching, C-reactive protein, ODDS ratio
Abstract

Summary: Background: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn's disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are currently not available or planned. Aim: To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective registry specifically developed for comparative studies with correction for confounders. Methods: Crohn´s disease patients, who failed anti‐TNF treatment and started vedolizumab or ustekinumab in standard care as second‐line biological, were identified in the observational prospective Dutch Initiative on Crohn and Colitis Registry. Corticosteroid‐free clinical remission (Harvey Bradshaw Index ≤4), biochemical remission (C‐reactive protein ≤5 mg/L and fecal calprotectin ≤250 µg/g), combined corticosteroid‐free clinical and biochemical remission, and safety outcomes were compared after 52 weeks of treatment. To adjust for confounding and selection bias, we used multiple logistic regression and propensity score matching. Results: In total, 128 vedolizumab‐ and 85 ustekinumab‐treated patients fulfilled the inclusion criteria. After adjusting for confounders, ustekinumab‐treated patients were more likely to achieve corticosteroid‐free clinical remission (odds ratio [OR]: 2.58, 95% CI: 1.36‐4.90, P = 0.004), biochemical remission (OR: 2.34, 95% CI: 1.10‐4.96, P = 0.027), and combined corticosteroid‐free clinical and biochemical remission (OR: 2.74, 95% CI: 1.23‐6.09, P = 0.014), while safety outcomes (infections: OR: 1.26, 95% CI: 0.63‐2.54, P = 0.517; adverse events: OR: 1.33, 95% CI: 0.62‐2.81, P = 0.464; hospitalisations: OR: 0.67, 95% CI: 0.32‐1.39, P = 0.282) were comparable between the two groups. The propensity score matched cohort with sensitivity analyses showed comparable results. Conclusions: Ustekinumab was associated with superior effectiveness outcomes when compared to vedolizumab, while safety outcomes were comparable after 52 weeks of treatment in CD patients who have failed anti‐TNF treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results